Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC

Liver International

Volumn 35, Issue 2, 2015, Pages 620-626

  Ricke, Jens ^a   Bulla, Karsten ^a   Kolligs, Frank ^b   Peck Radosavljevic, Markus ^c   Reimer, Peter ^d   Sangro, Bruno ^e   Schott, Eckart ^f   Schütte, Kerstin ^a   Verslype, Chris ^g   Walecki, Jerzy ^h   Malfertheiner, Peter ^a   Cwikla, J ^h   Gebauer, B ^f   Klumpen H ⁱ   Van Delden, O ⁱ   Rosmorduc, O ^j   Menu, Y ^j   Leroy, V ^k   Sengel, C ^k   Trumm, C ^b   Berg, T ^l   Moche, M ^l   Bilbao, I ^e   Gossner, L ^d   Popovic, P ^m   Stabuc, B ^m   Piasecki, P ⁿ   Podgajny, Z ⁿ   Sacco, R ^o   Bargellini, I ^o   Lammer, J ^c   Maleux, G ^g   Mayerle, J ^p   Rosenberg, C ^p   Nitsche, D ^q   Waldenberger, P ^q   Vergniol, J ^r   Cassinotto, C ^r   Yalcin, S ^s   Peynircioglu, B ^s   Zavaglia, C ^t   Rampoldi, A ^t   Tran, A ^u   Chevallier, P ^u   Anty, R ^u   Trautwein, C ^v   Kuhl, C ^v   Grazioli, L ^w   Vogl, T ^x   Trojan, J ^x   more..

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Karlsruhe Hospital   (Germany)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j HÔPITAL SAINT ANTOINE   (France)

^k HÔPITAL MICHALLON   (France)

^l UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^m UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

ⁿ Military Hospital Warszawa   (Poland)

^o UNIVERSITY HOSPITAL OF PISA   (Italy)

^p UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^q Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^r HAUT LÉVÊQUE HOSPITAL   (France)

^s HACETTEPE UNIVERSITY   (Turkey)

^t OSPEDALE NIGUARDA CA GRANDA   (Italy)

^u CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^v UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^w SPEDALI CIVILI   (Italy)

^x UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

SIRT; HCC; Hepatocellular carcinoma; Radioembolization; Safety; Sorafenib; Survival; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; SORAFENIB; TECHNETIUM 99M; YTTRIUM 90; CARBANILAMIDE DERIVATIVE; MICROSPHERE; NICOTINAMIDE; YTTRIUM;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; INFECTION; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ARTIFICIAL EMBOLISM; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; EUROPE; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PORTAL VEIN; PROCEDURES; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; EUROPE; FOLLOW-UP STUDIES; LIVER NEOPLASMS; MICROSPHERES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PORTAL VEIN; TREATMENT OUTCOME; YTTRIUM;

EID: 84921601923     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12622     Document Type: Article

References (25)

1. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
2. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
5. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
6. 90Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: a European evaluation. Hepatology 2011; 54: 868-78.
7. Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255: 955-65.
8. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507.
9. Moreno-Luna LE, Yang JD, Sanchez W, et al. Efficacy and safety of transarterial radioembolization vs. chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013; 36: 714-723.
10. Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012; 56: 464-73.
11. Sorafenib and micro-therapy guided by primovist enhanced MRI in patients With inoperable liver cancer (SORAMIC) http://clinicaltrials.gov/ct2/show/NCT01126645
12. Salem R, Thurston KG. Radioembolization with 90-yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 2006; 17: 1425-39.
13. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24: 293-8.
14. Chow PK, Poon D, Win KM, et al. Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05). J Clin Oncol, 2010; 28 (May 20 Supplement): 4072
15. Chow PK, Poon DY, Khin MW, et al. Asia-Pacific Hepatocellular Carcinoma Trials Group. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS ONE. 2014 Mar 10; 9: e90909. doi: 10.1371/journal.pone.0090909. eCollection 2014
16. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib patients with hepatocellular carcinoma (HCC) and Child-Pugh A vs. B cirrhosis. Gastrointest Cancer Res 2011; 4: 40-4.
17. Iñarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-12.
18. Seidensticker R, Seidensticker M, Damm R, et al. Hepatic toxicity afterradioembolization of the liver using (90)Y-microspheres: sequential lobar vs. whole liver approach. Cardiovasc Intervent Radiol 2012; 35: 1109-18.
19. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112: 1538-46.
20. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57: 1078-87.
21. Memon K, Kulik L, Lewandowski RJ, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 2013; 58: 73-80.
22. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo in combination with transarteerial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. Presented at the ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2012. J Clin Oncol 2012; (suppl. 4): abstr LBA154
23. Plastaras JP, Kim SH, Liu YY, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007; 67: 9443-54.
24. Gu K, Lai ST, Ma NY, et al. Hepatic regeneration after sub-lethal partial liver irradiation in cirrhotic rats. J Radiat Res 2011; 52: 582-91.
25. Poon RT, Lau C, Pang R, et al. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007; 14: 1835-45.